Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Zealand Pharma reports results from phase II trial of dasiglucagon

Aug. 12, 2016

Ascendis initiates phase III registration trial for TransCon growth hormone

Aug. 12, 2016

Protalix BioTherapeutics reports efficacy and safety data from phase I/II study of PRX-102

Aug. 11, 2016

JDRF enters development and discovery collaboration with Pacific Diabetes Technologies

Aug. 11, 2016

Phase II study of vTv Therapeutics' TTP-399 mets primary endpoint

Aug. 11, 2016

GRP45 shows promise as a therapeutic target for obesity

Aug. 10, 2016

Teijin and Versartis enter strategic alliance for development and commercialization of somavaratan

Aug. 10, 2016

FDA accepts Merck & Co.'s MK-1293 NDA for review

Aug. 8, 2016

Palatin Technologies gives update on bremelanotide phase III studies for HSDD

Aug. 5, 2016

Abeona Therapeutics cleared to conduct phase I/II study of gene therapy for MPS IIIA in Europe

Aug. 5, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 8, 2026.
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld Science
Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis
BioWorld Science
Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the...